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background or short axis > 10 mm on PET-CT were considered 
pathologic. Nodes between 5-10 mm were considered 
pathologic if the nodes had an irregular shape/border, had 
lost its architecture or were inhomogeneous. Eight patients 
were treated with lymphadenectomy prior to chemo-
radiation and did not receive a nodal boost. The remaining 75 
patients had a total number of 214 nodes boosted by EBRT 
(PTV-N) either as a simultaneous integrated boost (SIB) or as 
a sequential boost to 55-60Gy. The elective whole pelvic 
target (PTV-E) was treated to 45-50 Gy (Table 1). PTV-E was 
extended to the para-aortic region (PAN) in case of 
pathological nodes in the common iliac region or higher. 
Concomitant Cisplatin was given to 95% of the patients. MRI 
was performed 3 and 12 months after completion of 
treatment in all patients, 82/140 of the patients also had a 
PET-CT at 3 months follow-up. Additional imaging was 
performed on clinical indication. The total dose to PTV-N was 
calculated by rigidly registration of dose maps from elective 
EBRT, EBRT boost and IGABT to the planning CT scan. All 
doses were converted to EQD2 by the linear quadratic model 
(α/β = 10, repair halftime 1.5 h). 
 
Results: Pathological lymph node volume was on average 1.5 
cm3 (range 0.1-44.9) and average total dose was 62.4 Gy 
EQD2 (range 51.0-69.1). At a median follow-up time of 28 
months (range 3-64) five recurrences were diagnosed inside 
PTV-N. Each recurrent node was in a different patient. There 
was no significant impact of nodal dose for nodes receiving 
above or below 60 Gy EQD2 (Fischer's exact test, p=0.6) nor 
did we find any significance of nodal volume. (Figure 1). Two 
of the node positive patients had a new nodal recurrence 
within the PTV-E. One patient had multiple recurrences 
involving PTV-N, PTV-E, as well as distant metastases. Two of 
the node positive patients had recurrences in both PTV-E and 
outside in the PAN region. None of the 57 node negative 
patients experienced nodal recurrence in PTV-E. Nine 
patients (6%) recurred in PAN outside PTV-E without any 
other sites of recurrence. Four of these patients did not have 
nodal disease at time of diagnosis.  
Conclusions: Both micro- and macroscopic nodal control in 
locally advanced cervical cancer is high with the currently 
used treatment schedules. Recurrences are mainly located 
outside the PTV in the PAN region. Due to the limited number 
of recurrences in boosted nodes it has not been possible to 
establish a dose response relationship. 
   
PD-0438   
Adjuvant volumetric modulated arc therapy with vaginal 
cuff simultaneous integrated boost in endometrial cancer 
R. Mazzola1, F. Ricchetti2, S. Fersino2, N. Giaj Levra2, A. 
Fiorentino2, R. Ruggieri2, M. Ceccaroni3, S. Gori4, F. Alongi2 
1Sacro Cuore Don Calabria Negrar- Verona University of 
Palermo, Radiation Oncology, Palermo, Italy  
2Sacro Cuore Don Calabria Hospital, Radiation Oncology, 
Negrar Verona, Italy  
3Sacro Cuore Don Calabria Hospital, Ginecology Oncology, 
Negrar Verona, Italy  
4Sacro Cuore Don Calabria Hospital, Medical Oncology, 
Negrar Verona, Italy  
 
Purpose/Objective: Volumetric Modulated Arc Therapy 
RapidArc® (VMAT) has shown to be able to maintain a good 
toxicity profile in pelvic irradiation (PRT). We present our 
experience in treating pelvis for post-operative endometrial 
cancer (EC) with VMAT and simultaneous integrated boost 
(SIB) on vaginal cuff in patients (pts) unable to receive 
vaginal brachytherapy (VB). 
Materials and Methods: From September 2011 to December 
2013, fifty consecutive pts, submitted to hysterectomy with 
bilateral salpingo-oophorectomy and pelvic 
lymphadenectomy for EC, were candidate to PRT and VB +/- 
chemotherapy, according to stratification risk category. All 
the pts recruited refused VB for logistic problems or because 
unable or not willing to receive such treatment. After a 
specific informed consent, a dose of 54 Gy to the pelvis and 
66 Gy to the vaginal cuff in 30 fractions was delivered with 
SIB-VMAT technique. A 5 mm trans-vaginal probe and 
Magnetic Resonance Imaging were used to define vaginal 
cuff. All toxicity data were collected according to CTCAE 
v4.0; clinical outcomes were analyzed retrospectively.  
Results: Median FUP was 36 months (range, 12 to 39 months). 
According to FIGO 2009, the most representative stages 
were: IB1 (20% - 10/50), IB2 (28% - 14/50), IIA2 (16% - 8/50), IIB 
(6% - 3/50), IIIA (2% - 1/50), IIIC (28% - 14/50). The 2-year-OS 
and 2-year-LC were 96% and 100%. The 3-year-OS and LC 
were 96% and 87%. The median DFS was 25 months (range, 
12-30). No vaginal-cuff recurrence was registered. The only 
two loco-regional failures were pelvic-LNs metastases. Acute 
GI toxicity was registered as follow: G0 in 6 pts, G1 in 26 pts, 
G2 in 18 pts. No case of toxicity ≥ G3 was observed. Acute GU 
toxicity was: G0 in 5 pts, G1 in 21 pts, G2 in 24 pts. No case 
of toxicity ≥ G3 was observed. No late moderate - severe GI 
or GU toxicities were reported. A statistical correlation was 
found between acute G2 GI toxicity with Intestinal Cavity (IC) 
dose-constraints V20 Gy ≥ 30% (p-value = 0.02), V20 ≥ 40% (p 
= 0.02), V30 ≥ 30% (p = 0.004) and with IC-Dmax ≥ 45 Gy (p = 
0.001). Regarding GU assessment, the risk to develop G2 
acute toxicity is 3 times higher with adjuvant chemotherapy 
(p = 0.07).  
Conclusions: In EC pts unable to receive VB or refusing to 
receive this treatment, SIB-VMAT could be a viable 
alternative. The present analyses showed promising findings. 
Further prospective studies are advocated.  
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Purpose/Objective: Computerized Axial Tomography (CAT) 
scan assistance during planning Interstitial Brachytherapy 
(ISBT) with Oncentra based Inverse Planning and Simulated 
Annealing (IPSA) is used in different Institutes. ISBT has 
become an integral part for treatment of gynaecologic 
malignancies. This is an attempt to present the dose schedule 
used and analyse the outcome and radiation morbidity 
encountered.  
Materials and Methods: An institutional prospective 
analytical study since May, 2012 to May, 2014 was 
undertaken. A total of 50 cases of FIGO stage IIB to IIIB 
including 25 post operative cases of Ca. Cervix (42 Ca. Cervix 
and 8 Ca.Vagina) with 100 ISBT sessions using Martinez 
Universal Perineal Template (MUPIT) were done. Analysis was 
done in the month of Sept, 2014. All the patients underwent 
whole pelvis External Beam Radiation Therapy (EBRT) 4500 
cGy in 25 Fractions, followed by midline shielding till total 
dose of 5040 cGy in 28 fractions @ 180 cGy per fraction, 5 
days a week, with weekly Cisplatin 40 mg/m2 prior to ISBT. A 
gap of 7 to10 days was allowed after completion of EBRT 
before attempting ISBT. The anatomical relations with 
Uterus, Bladder, Rectum and Intestines were noted from pre 
implant CT Scan of the pelvis. Gap of 7-10 days between ISBT 
applications was allowed and dose ranged from 800-950 cGy 
per session. The dose to CTV, Urinary Bladder and Rectum is 
reviewed, with importance to Biological Equivalent Dose 
(BED). RTOG/ECOG criteria were used to analyse vaginal 
mucosal / bowel/ bladder early and late radiation morbidity. 
Results: There was only one case of hematuria following 
implant removal, and one case of rectal wall perforation was 
noted during the procedure. The mean dose to CTV D90 is 
8.74Gy and 0.1cc, 1cc, 2cc of Bladder and Rectum were 
8.01Gy, 6.75Gy, 6.29Gy and 7.36Gy, 6.49Gy, 6.02Gy 
respectably. The BED 8.74Gy for tumour is 85.8Gy (EBRT + 2 
sessions of IBT) with homogeneity index of. With median 
follow up of 16 months (range 4 -24 months) 3 patients had 
grade 3 vaginal mucosal toxicity, 5 patients had grade 3 
toxicity of bladder and no grade 3/4 rectal toxicity noted.  
Conclusions: The procedure is well tolerated by the patients. 
There were no immediate post procedure complications. 
Total duration of the process from spinal anaesthesia to 
removal of template is within 3 hours. This study present the 
dose schedules and fractionation which has less patient 
distress for lying in bed with the perineal template 
continuously for two to three days with comparable few 
toxicity levels. 
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Purpose/Objective: To present our first clinical experiences 
with combined intracavitary/interstitial (IC/IS) pulsed- dose-
rate brachytherapy (PDR-BT) for locally advanced cervical 
cancer using same-day MRI preplanning. 
Materials and Methods: Ten patients (FIGO IIB-IIIB) were 
treated with plastic tandem-ring (T-R, Varian) applicator 
using a custom made needle cap. For all patients treatment 
was started with pelvic±paraaortic IMRT (50.4 Gy ± 58.8 Gy 
simultaneously integrated boost to positive lymph nodes) 
with concurrent cisplatin. BT was performed on the 6th-7th 
week of the treatment. Two BT implants (BT1, BT2) followed 
by 3D SPACE MRIs with the T-R applicator in situ were 
performed in the same day in epidural anesthesia. The BT1 
was used for trajectory planning of IS needles while BT2 
comprised 35 Gy of PDR BT in 50 pulses with the implanted 
needles. Patients were re-planned without needles 
(optimized IC plan: oIC) as well. The optimization was 
stopped when the same D2cc dose parameters for OARs were 
achieved as with IC/IS approach. Dose parameters were 
compared by Wilcoxon signed-rank test. 
Results: The number of implanted IS needles was 4±1 
(Mean±SD). The depth of insertion was 25±15 mm. The 
majority (80%) of the needles was inserted in the postero-
lateral positions of the ring. The mean D90 and D98 for HR-
CTV was 90±6.2 Gy and 81.4±6.2 Gy, while for D90 IR-CTV 
was 69.5±2.9 Gy, respectively. The mean D2cc for OARs were 
the followings: bladder: 77±3 Gy, rectum: 64±3.4 Gy, 
sigmoid: 61.3±4.5 Gy and intestine: 63.8±6.4 Gy. Optimized 
IC plan significantly decreased D90 (82.5 vs. 90 Gy, p= 0.03) 
and D98 (73.9 vs. 81.4 Gy, p=0.01) for HR CTV compared to 
IC/IS at the same D2cc parameters for OARs. No serious 
perioperative complications were observed.  
Conclusions: Combined IC/IS BT based on same-day 3D MRI 
trajectory pre-planning seems to be clinically feasible 
resulting in accurate needle placement with superior 
dosimetric results compared to optimized IC plan.  
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Purpose/Objective: With about 500 000 new cases every 
year, cervical cancer is the fourth most common cancer 
affecting women worldwide, and still more than half of 
women die from the disease. There were 2783 new cases in 
Poland in 2012. Tumor volume and nodal involvement are 
prognostic of worse outcome. The purpose of this study was 
to characterize the parameters of the tumor of cervical 
cancer obtained from FDG-PET/CT and FLT-PET/CT imaging 
before radiotherapy treatment planning and to assess their 
influence on treatment decision. 
Materials and Methods: 28 patients with histological 
confirmed cervical cancer (27 planoepitheliale cancer, 1 
clarocellulare, 2pts with G1, 13pts G2, 3pts G3, 10pts G is 
not known) with FIGO stage II (12pts) and FIGO III (16pts) 
were enrolled in this study. The mean age was 52 +/-12 (SD) 
years. Routinely the patients have undergone blood analysis 
(hemoglobin and white blood cells level ) and vaginal 
bacteriology before treatment. They were examined with FLT 
PET and FDG PET.in years 2012-2014 with Gemini TF PET/CT 
scanner (Philips). PET scans were acquired on separate days 
(within one week) 60min after IV injection of 300MBq of 18F-
FDG (F-con) and 300MBq of 18F-FLT (Iason). The same scan 
protocol and reconstruction algorithms were used for both 
scans. Based on MRI calculations and phantom studies a 43% 
threshold cut-off value was selected for metabolic GTV 
delineation and volume calculation. Metabolic parameters of 
the tumor, tumor volume and clinical parameters were 
assessed on every scan separately. Data were statistical 
analyzed using p<0.05. 
Results: In all patients both tracers showed increased uptake 
in the primary tumor. The SUVmax and SUVmean were in 
general lower for FLT-GTV than FDG-GTV (7,3±2,18 vs 
12,3±4,2; p<0.001 and 4,11±1,39 vs 6,9±2,39; p<0.001). 
However, in three patients SUV values for FLT-GTV were 
